JN.1与KP.2新冠mRNA疫苗对新出现的SARS-CoV-2变异株的免疫原性
本研究在德国和美国参与者中分别评估JN.1与KP.2 mRNA加强针的免疫原性,两者对JN.1、KP.2及LP.8.1.1、NB.1.8.1等全球相关变异株均诱导强劲且相似的中和抗体应答;数据提示将疫苗配方更新为抗原性密切相关的毒株对当前流行变异株可能仅带来有限的额外益处。
要点
- JN.1与KP.2 mRNA加强针均对JN.1、KP.2及LP.8.1.1、NB.1.8.1诱导强劲中和抗体应答。
- 两种疫苗诱导的中和抗体应答相似。
- 将疫苗配方更新为密切相关的毒株对当前流行变异株可能仅带来有限的额外益处。
核心结论
- JN.1与KP.2 mRNA加强针均诱导针对JN.1、KP.2及LP.8.1.1、NB.1.8.1等全球相关变异株的强劲且相似的中和抗体应答。
- 数据提示将疫苗配方更新为抗原性密切相关的毒株对当前流行变异株可能仅带来有限的额外益处。
研究设计与样本
- 研究评估JN.1与KP.2 mRNA加强针的免疫原性,参与者分别来自德国和美国。
主要发现
- JN.1与KP.2 mRNA加强针均对JN.1、KP.2及LP.8.1.1、NB.1.8.1等全球相关变异株诱导强劲中和抗体应答。
- 两种疫苗诱导的中和抗体应答相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to evolve five years after the initial outbreak. Although mRNA vaccines encoding the JN.1 and KP.2 Spike proteins were authorized in fall 2024, it remains unclear whether vaccine updates will be necessary for variants containing antigenically closely related Spike proteins. In this study, we evaluated the immunogenicity of JN.1 and KP.2 mRNA boosters in participants from Germany and the United States, respectively. Both vaccines induced robust and similar neutralizing antibody responses against JN.1, KP.2, and other globally relevant variants such as LP.8.1.1 and NB.1.8.1. These data suggest that updating the vaccine formulation to closely related strains will likely offer only modest additional benefits against currently circulating variants.
引用
- Lasrado N, Rössler A, McConnell I, et al. Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants. Vaccine. 2025. PMID: 41265004. doi:10.1016/j.vaccine.2025.127997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。